. 2022 Jun 17;19:65–80. doi: 10.1016/j.ijpddr.2022.05.005

Table 2.

Evaluation of the white blood cells with differential absolute leukocyte count at the beginning and end of the experimental period.

		NI_S_AP	NI_Epo_AP	I_S_AP	I_Epo_AP	NI_S_CP	NI_Epo_CP	I_S_CP	I_Epo_CP
WBC (x10³/mm³)	d0	10.50 ± 1.84^A	4.95 ± 1.21^A	11.90 ± 2.10^A	6.54 ± 1.53^A	4.30 ± 1.14	4.34 ± 1.09^A	3.76 ± 0.44^A	5.09 ± 2.61^A
WBC (x10³/mm³)	d180	2.08 ± 0.81^Ba	5.75 ± 1.20^Aab	6.02 ± 1.60^Bb	6.24 ± 1.96^Ab	2.69 ± 1.14^a	2.66 ± 0.47^Ba	6.87 ± 3.07^Bb	7.52 ± 0.68^Ab
Lymphocytes (x10³/mm³)	d0	8.81 ± 1.30^A	4.04 ± 1.03^A	9.75 ± 1.58^A	5.65 ± 1.38^A	3.62 ± 1.06^A	3.70 ± 0.93^A	2.87 ± 0.30^A	4.09 ± 2.08^A
Lymphocytes (x10³/mm³)	d180	1.64 ± 0.73^Ba	4.99 ± 1.16^Abc	3.87 ± 1.98^Bab	5.12 ± 1.79^Ac	2.05 ± 0.94^Bab	1.97 ± 0.48^Bab	2.76^#Aab	6.03 ± 0.84^Ac
Monocytes (x10³/mm³)	d0	0.32 ± 0.16^A	0.13 ± 0.06^A	0.41 ± 0.43^A	0.19 ± 0.13^A	0.10 ± 0.09^A	0.15 ± 0.12^A	0.12 ± 0.06^A	0.13 ± 0.07^A
Monocytes (x10³/mm³)	d180	0.24 ± 0.24^A	0.16 ± 0.15^A	0.84 ± 0.11^A	0.51 ± 0.15^B	0.26 ± 0.32^A	0.15 ± 0.48^A	0.24^#A	0.54 ± 0.22^B
Segmented neutrophils (x10³/mm³)	d0	1.33 ± 0.67^Abc	0.74 ± 0.23^Aab	2.19 ± 0.74^Ac	0.63 ± 0.33^Aab	0.55 ± 0.07^Aab	0.46 ± 0.09^Aa	0.63 ± 0.20^Aab	0.82 ± 0.57^Aab
Segmented neutrophils (x10³/mm³)	d180	0.24 ± 0.11^B	0.61 ± 0.11^A	1.14 ± 0.96^A	0.55 ± 0.10^A	0.35 ± 0.20^A	0.54 ± 0.24^A	0.60^#A	0.90 ± 0.35^A
Eosinophils (x10³/mm³)	d0	0.04 ± 0.06^A	0.04 ± 0.04^A	0.00 ± 0.00^A	0.07 ± 0.07^A	0.03 ± 0.03^A	0.03 ± 0.02^A	0.01 ± 0.02^A	0.02 ± 0.04^A
Eosinophils (x10³/mm³)	d180	0.03 ± 0.03^A	0.00 ± 0.00^A	0.54 ± 0.99^A	0.06 ± 0.06^A	0.03 ± 0.03^A	0.00 ± 0.00^B	0.00 ± 0.00^A	0.05 ± 0.04^A

Values are means ± standard deviation.

Different uppercase letters in the same column within the variable are significantly different (p ≤ 0.05).

Different lower-case letters in the same row are significantly different (p ≤ 0.05).

#Value of just one mouse.

WBC: white blood cells. d0: the beginning of the study. d180: end of the trial. NI_S_AP: uninfected and treated with saline between d1 and d30. NI_Epo_AP: uninfected and treated with erythropoietin (Epo) between d1 and d30. I_S_AP: infected with T. cruzi and treated with saline in the acute phase (d1 to d30). I_Epo_AP: infected and treated with Epo in the acute phase. NI_S_CP: uninfected and treated with saline between d90 and d120. NI_Epo_CP: uninfected and treated with Epo between d90 and d120. I_S_CP: infected with T. cruzi and treated with saline in the chronic phase (d90 to d120). I_Epo_CP: infected and treated with Epo in the chronic phase.